are compounded glp 1 still available New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may be producing these drugs at scale. Our Compounded GLP-1 injection - Personalized

Several candidates are advancing through clinical development, including orforglipron, currently in Phase III trials for obesity and type 2 diabetes

consumer audience

While dietary fiber supports digestive health long-term, suddenly increasing fiber intake while starting semaglutide can worsen diarrhea

This path focuses on sustainable changes to nutrition, physical activity, sleep, and stress management

Tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors, improving insulin sensitivity and promoting fullness, leading to superior weight losssome patients lose over 20%, with an average of 15%

As a result many clinicians who prescribe them question their sustainability